Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.81 |
| ▸ | PARP11 | Q9NR21 | 6/20 | 0.81 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.64 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.64 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.64 |
| ▸ | PARP1 | P09874 | 10/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999788 | 0.89 | PARP10 (1.00) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL29644368 | 0.89 | PARP10 (1.00) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| Toluene SCHEMBL29027038 | 0.80 | PARP10 (0.79) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL5076461 | 0.79 | PARP1 (0.81) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL1333810 | 0.78 | CLK4 (1.00) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL12546313 | 0.78 | PARP10 (0.81) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL1661783 | 0.74 | PARP10 (0.53) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL7920173 | 0.74 | PARP10 (0.53) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL29476168 | 0.74 | PARP10 (0.44) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL8650202 | 0.74 | PARP10 (0.44) | PARP10PARP11PIM1CSNK1A1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448363-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4558483-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-115867346-B | Kinase inhibitors | GB005股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119546576-A | Novel isoquinolinones pyrrolo-pyridones and thieno pyridone sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024017856-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4157446-A1 | KINASE INHIBITORS | GB002, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115867346-A | Kinase inhibitors | GB005股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3464286-B1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3464286-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448363-B2 | Kinase inhibitors | BTK, ABL1, LYN | PARP10 732/4885PARP11 698/4885PIM1 255/4885 |
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | PARP10 99/4885PARP11 61/4885PIM1 2774/4885 |
| US-20230219923-A1 | KINASE INHIBITORS | BTK, ABL1, LYN | PARP10 732/4885PARP11 698/4885PIM1 255/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | PARP10 99/4885PARP11 61/4885PIM1 2774/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | PARP10 99/4885PARP11 61/4885PIM1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.